AU2005259481B2 - Improved adjuvant therapy of G250-expressing tumors - Google Patents

Improved adjuvant therapy of G250-expressing tumors Download PDF

Info

Publication number
AU2005259481B2
AU2005259481B2 AU2005259481A AU2005259481A AU2005259481B2 AU 2005259481 B2 AU2005259481 B2 AU 2005259481B2 AU 2005259481 A AU2005259481 A AU 2005259481A AU 2005259481 A AU2005259481 A AU 2005259481A AU 2005259481 B2 AU2005259481 B2 AU 2005259481B2
Authority
AU
Australia
Prior art keywords
antibody
antigen
patients
week
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005259481A
Other languages
English (en)
Other versions
AU2005259481A1 (en
Inventor
Sven Warnaar
Olaf Wilhelm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Publication of AU2005259481A1 publication Critical patent/AU2005259481A1/en
Application granted granted Critical
Publication of AU2005259481B2 publication Critical patent/AU2005259481B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2005259481A 2004-07-02 2005-06-29 Improved adjuvant therapy of G250-expressing tumors Expired AU2005259481B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US60/584,679 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (2)

Publication Number Publication Date
AU2005259481A1 AU2005259481A1 (en) 2006-01-12
AU2005259481B2 true AU2005259481B2 (en) 2010-04-22

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005259481A Expired AU2005259481B2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of G250-expressing tumors

Country Status (13)

Country Link
US (1) US7691375B2 (enExample)
EP (2) EP2497497B1 (enExample)
JP (1) JP2008505143A (enExample)
KR (1) KR101205289B1 (enExample)
CN (1) CN101052416B (enExample)
AU (1) AU2005259481B2 (enExample)
BR (1) BRPI0512854A (enExample)
CA (1) CA2566950A1 (enExample)
DK (1) DK2497497T3 (enExample)
ES (1) ES2641089T3 (enExample)
MX (1) MXPA06013240A (enExample)
RU (2) RU2371198C2 (enExample)
WO (1) WO2006002889A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
CA2492057A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
EP2479577A1 (en) 2009-09-18 2012-07-25 Mitsubishi Chemical Corporation Hepatocellular carcinoma marker
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105377295A (zh) 2013-02-22 2016-03-02 威丽克斯股份公司 基于caix分级的癌症治疗
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
ES2365606T3 (es) * 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
CA2492057A1 (en) * 2002-07-01 2004-01-08 Wilex Ag Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEFFENS, M.G. et al., Clinical Cancer Research, 1999, Vol. 5, pages 3268S-74S *

Also Published As

Publication number Publication date
EP1763367A2 (en) 2007-03-21
WO2006002889A2 (en) 2006-01-12
JP2008505143A (ja) 2008-02-21
ES2641089T3 (es) 2017-11-07
CN101052416A (zh) 2007-10-10
WO2006002889A3 (en) 2006-10-05
MXPA06013240A (es) 2007-02-28
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
CA2566950A1 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
AU2005259481A1 (en) 2006-01-12
US20070207157A1 (en) 2007-09-06
RU2371198C2 (ru) 2009-10-27
EP2497497A1 (en) 2012-09-12
KR20070036085A (ko) 2007-04-02
RU2519340C2 (ru) 2014-06-10
US7691375B2 (en) 2010-04-06
EP2497497B1 (en) 2017-06-21
RU2007104040A (ru) 2008-08-10
KR101205289B1 (ko) 2012-11-27
BRPI0512854A (pt) 2008-04-08

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20170327578A1 (en) Anti-ceacam1 recombinant antibodies for cancer therapy
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
KR20170060042A (ko) Alk 억제제의 조합 요법
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
CN112292151A (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN113244385A (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN113244386A (zh) 抗pd-1抗体在治疗肿瘤中的用途
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
HK40055783A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40055783B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired